(Original title: Free imitation of new crown special drugs, 5 Chinese pharmaceutical companies are authorized. The State Council issued a heavy document to launch inbound tourism promotion actions in a timely manner, and the concept stocks that institutions are optimistic about are released)
The State Council issued the “14th Five-Year Plan for Tourism Development”, proposing to promote inbound tourism step by step and steadily develop outbound tourism under the premise that the international epidemic is effectively controlled.
5 Chinese pharmaceutical companies approved to imitate Merck’s new crown oral liquid
On January 20, the Medicines Patent Pool (MPP) announced that it has signed agreements with 27 companies to produce Merck’s oral COVID-19 antiviral drug molnupiravir, which will be produced and supplied to 105 low- and middle-income countries or regions around the world A high-quality, affordable generic version of the oral anti-coronavirus drug Molnupiravir.
Among them, 5 companies will focus on the production of APIs, 13 companies will produce both APIs and preparations, and 9 companies will produce preparations. These companies are present in 11 countries around the world including Bangladesh, China, Egypt/Jordan, India, Indonesia, Kenya icon, Pakistan, South Africa, South Korea and Vietnam.
The information also shows that there are a total of 5 companies qualified for imitation in China, including Fosun Pharma, Langhua Pharma, Longze Pharma, Borui Pharma, and Desano Pharma.
As COVID-19 is still classified as a public health emergency of international concern by the World Health Organization (WHO). As a result, neither Merck, Ridgeback, nor Emory University, which invented the drug, would receive royalties on sales of molnupiravir from sublicensors authorized by the MPP.
Recently, in the A-share market, stocks related to the treatment of new coronary pneumonia have risen sharply. However, the main funds have sold sharply. Data treasure statistics, from the first day of 2022 to January 20, 12 new crown special medicine concept stocks, the main capital net outflow exceeded 2.2 billion yuan, the net outflow of Aoxiang Pharmaceutical and Beihua shares exceeded 500 million yuan, Junshi Biotechnology, The net inflow of Tuoxin Pharmaceutical exceeded 250 million yuan. Among them, Junshi Bio’s new crown oral drug VV116 was approved for emergency use authorization in Uzbekistan, and Tuoxin Pharmaceutical was expected to bind real biological azvudine.
Tourism “14th Five-Year Plan” released
According to Xinhua News Agency, the State Council issued the “14th Five-Year Plan for Tourism Development”, which proposed to timely study and judge the situation of domestic and foreign new crown pneumonia epidemic prevention and control, the development and changes of the international environment, and scientifically adjust the management measures for relevant personnel to come to China to ensure the safety of epidemic prevention. On the premise of building a healthy, safe and orderly exchange of Chinese and foreign personnel. The promotion of inbound tourism will be launched in a timely manner, and policies to support the development of inbound tourism will be introduced.
The plan proposes to promote the integrated development of tourism in the Guangdong-Hong Kong-Macao Greater Bay Area, support the prosperity and development of Hong Kong’s tourism industry, promote the construction of Macau’s world tourism and leisure center, and support Macau in hosting the World Tourism Economy Forum and the International Tourism (Industry) Expo.
The tourism plan is clear. By 2025, the level of tourism development will continue to improve, the modern tourism system will be more complete, the effective supply of tourism, high-quality supply, and flexible supply will be more abundant, and mass tourism consumption needs will be better satisfied.
Tourism revenue in 2020 falls to levels of eight years ago
Tourism is an indispensable part of GDP contribution. According to the National Bureau of Statistics, the domestic tourism revenue in 2019 exceeded 55 trillion yuan, a record high. During the “13th Five-Year Plan” period, the development of inbound and outbound tourism was healthy and orderly, and the total number of inbound and outbound tourists per year exceeded 300 million. Tourism is also one of the industries most seriously affected by the new crown epidemic. In 2020, tourism revenue dropped to 2.23 trillion yuan, a cliff-like decline from 2019 tourism revenue and returned to the level of 8 years ago (2012).
From the perspective of the contribution of tourism revenue to GDP, it rose steadily from 2010 to 2019. In 2019, the contribution reached a record high of 5.8%, but only 2.2% in 2020.
In the future, on the basis of ensuring safety, promoting inbound tourism will be beneficial to the tourism industry in 2022. Since December 21 last year, the A-share tourism sector index has rebounded by more than 12%, and has risen by 5.2% this year.
8 travel stocks rose more than 10%
Under the influence of the epidemic, listed companies in the tourism industry have suffered heavy losses in both stock prices and performance. Compared with 2020, the performance of listed companies in the tourism industry will recover in 2021. With the Spring Festival approaching, the tourism market is expected to improve. The China Tourism Academy predicts that in 2022, the number of domestic tourists will be 3.980 billion, and the domestic tourism revenue will be 3.81 trillion yuan, a year-on-year increase of 16% and 27%, respectively, returning to 70% of the level in the same period in 2019.
According to statistics from Securities Times·Databao, the total market value of the 23 stocks in the tourism sector is nearly 500 billion yuan. The market value of China Duty Free China Duty Free Mao is as high as 378.546 billion yuan. Songcheng Performing Arts, CYTS, and Yunnan Tourism all have a market value of more than 7 billion yuan.
From the perspective of performance, CDFG’s 2021 performance is expected to increase. Huangshan Tourism, Mount Emei A, CYTS and Songcheng Performing Arts Agency predict that the net profit in 2021 may double, of which Huangshan Tourism will make a small profit of 25 million yuan in the first three quarters of 2021.
In terms of upside potential, 8 institutions unanimously predict that the target price will increase by more than 10% compared with the latest price, China CDFG, Tibet Tourism, and Guilin Tourism all exceed 40%, and three stocks such as Sante Cableway and Songcheng Performing Arts exceed 15%.
Disclaimer: All information content of Databao does not constitute investment advice. The stock market is risky, and investment should be cautious.